Tofacitinib for Treatment of Moderate COVID-19 (I-TOMIC)
Diseases of the Respiratory Systems | COVID-19 Inpatient
What is the purpose of this trial?
The purpose of this randomized, double blinded, placebo controlled study is to assess the efficacy and safety of tofacitinib in hospitalized adult (18-65 years old) patients with SARS-CoV-2 and pneumonia who require supplemental oxygen and have serologic markers of inflammation but do not need mechanical ventilation.
- Trial withYale University School of Medicine
- Start Date09/02/2020
- End Date12/30/2020
- Last Updated09/04/2020
- Study HIC#2000027848